4147 Stock Overview
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TaiMed Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$79.90 |
| 52 Week High | NT$116.50 |
| 52 Week Low | NT$66.60 |
| Beta | 0.33 |
| 11 Month Change | -1.11% |
| 3 Month Change | -1.36% |
| 1 Year Change | -4.88% |
| 33 Year Change | 12.06% |
| 5 Year Change | -41.47% |
| Change since IPO | 284.13% |
Recent News & Updates
Recent updates
TaiMed Biologics Inc.'s (GTSM:4147) Profit Outlook
Apr 20
TaiMed Biologics Inc. (GTSM:4147) Analysts Just Trimmed Their Revenue Forecasts By 18%
Mar 16TaiMed Biologics'(GTSM:4147) Share Price Is Down 67% Over The Past Five Years.
Feb 09Loss-Making TaiMed Biologics Inc. (GTSM:4147) Set To Breakeven
Jan 05
TaiMed Biologics (GTSM:4147) Has Debt But No Earnings; Should You Worry?
Dec 01Shareholder Returns
| 4147 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -0.7% | -1.0% | 0.8% |
| 1Y | -4.9% | 0.7% | 30.3% |
Return vs Industry: 4147 underperformed the TW Biotechs industry which returned 0.7% over the past year.
Return vs Market: 4147 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 4147 volatility | |
|---|---|
| 4147 Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 4.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4147 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4147's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Jimmy Chang | www.taimedbiologics.com |
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody.
TaiMed Biologics Inc. Fundamentals Summary
| 4147 fundamental statistics | |
|---|---|
| Market cap | NT$21.81b |
| Earnings (TTM) | -NT$141.64m |
| Revenue (TTM) | NT$622.61m |
35.0x
P/S Ratio-154.0x
P/E RatioIs 4147 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4147 income statement (TTM) | |
|---|---|
| Revenue | NT$622.61m |
| Cost of Revenue | NT$351.99m |
| Gross Profit | NT$270.63m |
| Other Expenses | NT$412.27m |
| Earnings | -NT$141.64m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 43.47% |
| Net Profit Margin | -22.75% |
| Debt/Equity Ratio | 12.1% |
How did 4147 perform over the long term?
See historical performance and comparison